CNS Pharmaceuticals (CNSP) Enterprise Value (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Enterprise Value came in at -$7.2 million in Q4 2025, down 11.45% YoY from -$8.1 million in Q4 2024, and up 27.0% on a QoQ basis from -$9.9 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Enterprise Value (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Enterprise Value data on file, last reported at -$7.2 million in Q4 2025.
- Quarterly Enterprise Value fell 11.45% year-over-year to -$7.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.2 million (down 11.45% YoY) and the FY2025 annual result came in at -$7.2 million, down 11.45% from the prior year.
- Enterprise Value improved to -$7.2 million in Q4 2025, from -$9.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$548721.0 in Q4 2023 to a low of -$13.0 million in Q1 2025.
- A 5-year average of -$6.9 million and a median of -$7.0 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value soared 94.54% — and 2025, when it sank 1500.49%.
- Tracing CNSP's Enterprise Value over 5 years: stood at -$5.0 million in 2021, then slumped by 100.93% to -$10.1 million in 2022, then soared by 94.54% to -$548721.0 in 2023, then slumped by 1077.53% to -$6.5 million in 2024, then dropped by 11.45% to -$7.2 million in 2025.
- The last three Enterprise Value figures came in at -$7.2 million (Q4 2025), -$9.9 million (Q3 2025), and -$12.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | -7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.20 Mn |
| Sep 30, 2025 | -9.86 Mn |
| Jun 30, 2025 | -12.13 Mn |
| Mar 31, 2025 | -13.05 Mn |
| Dec 31, 2024 | -6.46 Mn |
| Sep 30, 2024 | -6.97 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -815,226.00 |
| Dec 31, 2023 | -548,721.00 |
| Sep 30, 2023 | -909,547.00 |
| Jun 30, 2023 | -4.28 Mn |
| Mar 31, 2023 | -5.11 Mn |
| Dec 31, 2022 | -10.06 Mn |
| Sep 30, 2022 | -7.03 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -12.44 Mn |
| Dec 31, 2021 | -5.00 Mn |
| Sep 30, 2021 | -8.33 Mn |
| Jun 30, 2021 | -6.89 Mn |
| Mar 31, 2021 | -11.08 Mn |